Equibles does not estimate personal net worth.
Get an email with a short summary when Madrigal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MDGL alertsThe proxy statement of Madrigal Pharmaceuticals, Inc. reports total compensation of $9,190,678 for David Soergel in fiscal 2025, including a base salary of $418,182. David Soergel has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Madrigal Pharmaceuticals, Inc. on July 30, 2026. Madrigal Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Madrigal Pharmaceuticals, Inc. includes Bill Sibold (CEO and Board Member), Julian C. Baker (Chairman and Board Member), Mardi Dier (CFO) and 7 others.
“As Bill just mentioned, for a therapy to be truly foundational, it should work effectively across patient subgroups. This is especially true in a heterogeneous disease like MATCH.”
“Our objective at R&D is straightforward. Deliver the industry-leading pipeline in MASH to make better therapies for patients with ResDifera as the Foundation.”
“So this is an incredibly high unmet need population. So I think the answer is it's really something that achieves statistical significance and is provable and can get to patients, absolutely.”
Proxy statement
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Madrigal Pharmaceuticals, Inc. (MDGL) | Executive Vice President and Chief Medical Officer | $418,182 | $9,190,678 |
